Figure 1 (IMAGE) Impact Journals LLC Caption Genetic alterations of SLC25A32 reduce survival of cancer patients. (A) Representation of SLC25A32 genetic alterations across different cancers (www.cbioportal.org). (B) Spearman's rank correlation between SLC25A32 mRNA expression (RSEM TPM) and somatic copy number in breast cancer (1075 sample; P < 0.05), ovarian cancer (300 sample; P = 0.0.05) and liver cancer (364 sample; P = 0.05) in patient samples of TCGA. Each dot represents a tumor sample of one particular patient. The dotted line represents a linear regression line and the blue area around the fitted line shows the 95% confidence intervals. (C) Median overall survival data of ovarian carcinoma patients with SLC25A32 amplification (67 cases) and no amplification (241 cases). Median survival difference between the two groups is statistically significant (P = 0.0435). (D) Median overall survival data obtained from breast carcinoma patients with SLC25A32 amplification (407 cases) and no amplification (1459 cases) are presented. Median survival difference between the two groups is statistically significant (P = 0.0000228) Credit Sven Christian - sven.christian@bayer.com Usage Restrictions CCBY License Licensed content Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.